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Abstract
Background: Plasmodium falciparum in vitro growth inhibition assays are widely used to evaluate and quantify the 
functional activity of acquired and vaccine-induced antibodies and the anti-malarial activity of known drugs and novel 
compounds. However, several constraints have limited the use of these assays in large-scale population studies, 
vaccine trials and compound screening for drug discovery and development.
Methods: The D10 P. falciparum line was transfected to express green fluorescent protein (GFP). In vitro growth 
inhibition assays were performed over one or two cycles of P. falciparum asexual replication using inhibitory polyclonal 
antibodies raised in rabbits, an inhibitory monoclonal antibody, human serum samples, and anti-malarials. Parasitaemia 
was evaluated by microscopy and flow cytometry.
Results: Transfected parasites expressed GFP throughout all asexual stages and were clearly detectable by flow 
cytometry and fluorescence microscopy. Measurement of parasite growth inhibition was the same when determined 
by detection of GFP fluorescence or staining with ethidium bromide. There was no difference in the inhibitory activity 
of samples when tested against the transfected parasites compared to the parental line. The level of fluorescence of 
GFP-expressing parasites increased throughout the course of asexual development. Among ring-stages, GFP-
fluorescent parasites were readily separated from uninfected erythrocytes by flow cytometry, whereas this was less 
clear using ethidium bromide staining. Inhibition by serum and antibody samples was consistently higher when tested 
over two cycles of growth compared to one, and when using a 1 in 10 sample dilution compared to 1 in 20, but there 
was no difference detected when using a different starting parasitaemia to set-up growth assays. Flow cytometry 
based measurements of parasitaemia proved more reproducible than microscopy counts.
Conclusions: Flow cytometry based assays using GFP-fluorescent parasites proved sensitive and highly reproducible 
for quantifying the growth-inhibitory activity of antibodies and anti-malarials, with superior reproducibility to light 
microscopy, and are suitable for high-throughput applications.
Background
Malaria is a leading cause of morbidity and mortality
globally and the majority of malaria-related mortality is
caused by Plasmodium falciparum, particularly among
children [1-3]. Antibodies are thought to be an important
component of naturally acquired protective immunity
against P. falciparum malaria. A number of studies sug-
gest an association between antibody levels to merozoite
antigens measured by enzyme linked immunosorbent
assays (ELISA) and protection from malaria disease [4-
15]. However, ELISA results are affected by the purity,
folding, and boundaries of the recombinant proteins used
and cannot distinguish between functional antibodies
that may contribute to protection and non-functional
antibodies or blocking antibodies that could potentially
interfere with the activity of protective antibodies in
human samples [16-20].
Studies using rabbit polyclonal sera and monoclonal
antibodies (MAb) raised by vaccination with recombi-
nant merozoite antigens or affinity purified human anti-
bodies suggest that antibodies against merozoite antigens
are capable of interfering with merozoite invasion of the
RBC directly in in vitro assays [21-27]. Plasmodium falci-
parum asexual stage growth inhibition assays have been
used extensively in malaria research to measure the levels
of growth inhibitory antibodies in clinical and pre-clinical
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Page 2 of 12studies [16,28-35]. Growth inhibition assays are also used
extensively for testing the sensitivity of isolates to anti-
malarial drugs or screening compounds for anti-malarial
activity in drug development studies.
The most readily available, simplest and most widely
used method for measuring parasitaemia in growth inhi-
bition assays is light microscopy [29,30,33,36-40]. How-
ever, microscopy of thin films is labour-intensive, with
studies suggesting that the reproducibility of parasitae-
mia counts decreases with decreasing parasite density
and is affected by the distribution of parasites on the slide
[41,42].
High throughput approaches such as parasite lactate
dehydrogenase (pLDH), and amino acid incorporation
assays (hypoxanthine and isoleucine uptake assays) allow
easier assessment of parasite growth for large sample sets
[17,31,32,34,35,39,43,44]. However, since methods such
as pLDH, hypoxanthine and isoleucine uptake assays
measure metabolic activity, reduced signal may be caused
by inhibition of intraerythrocytic parasite development
as well as inhibition of invasion [43,45]. Flow cytometry-
based methods have been shown to be highly reproduc-
ible, scalable for efficient use in large sample sets and
comparable in terms of sensitivity to alternative methods
such as microscopy, hypoxanthine uptake and pLDH
assays [28,43,45-48].
In this study, growth inhibition assays were optimized
and GFP-labelled fluorescent parasites developed and
evaluated in growth inhibition assays using antibodies
and anti-malarials. Furthermore, the sensitivity and
reproducibility of flow cytometry for measuring parasite
growth inhibition by antibodies was examined and com-
pared to light microscopy. Previously, O'Donnell et al
developed transgenic P. falciparum parasites expressing
an antigenically distinct 19 kDa fragment of the merozo-
ite surface protein 1 (MSP1-19) orthologue from the
rodent malaria Plasmodium chabaudi [39]; evaluating
inhibition of the P. chabaudi MSP1-19 line versus para-
sites with the P. falciparum MSP1-19 sequence allowed
measurement of P. falciparum MSP1-19-specific inhibi-
tory antibodies. In this study, MSP1-19 specific growth
inhibition assays were used as a model as it allowed anti-
gen-specific inhibition to be distinguished from non-spe-
cific inhibitory activity. MSP1-19 appears to be a target of
protective immunity and is an important vaccine candi-
date currently under development.
Methods
Continuous culture of P. falciparum
Plasmodium falciparum parasites were cultured in Petri
dishes using human O+ erythrocytes (RBC) maintained at
2% haematocrit [43]. Parasites were grown in RPMI-
HEPES culture medium (pH 7.4) supplemented with 50
μg/ml hypoxanthine, 25 mM NaHCO3, 20 μg/ml gentam-
icin, 5% (vol/vol) heat inactivated pooled human serum
(various blood groups, collected by the Australian Red
Cross) and 0.25% Albumax II (Gibco, Auckland, New
Zealand). In some drug inhibition experiments 0.5%
Albumax was used with no human serum added. Cul-
tures were maintained in airtight boxes at 37°C in an
atmosphere of 1% O2, 4% CO2 and 95% N2. Parasites used
in these studies include the D10 clonal line, an isogenic
D10-P. chabaudi MSP1-19 parasite line in which the P.
chabaudi orthologue replaces the region of P. falciparum
msp1 encoding MSP1-19 (known as PcMEGF), and an
isogenic D10-P. falciparum MSP1-19 parasite line gener-
ated in the same manner as PcMEGF to act as a transfec-
tion control (PfM3').
PfMSP1-19 specific growth inhibition assays
The protocol for measurement of antibody inhibition of
parasite growth used in this study was modified from
Persson et al [43]. PfMSP1-19 and PcMSP1-19 trans-
fected lines were maintained on 24 ng/ml pyrimethamine
(to select for MSP1-19 transfectants, Sigma Aldrich, St
Louis, MO, U.S.A.) with 5 μg/ml blasticidin-S-HCl (to
select for fluorescent transfectants, Invitrogen, Carlsbad,
CA, U.S.A.) added when culturing double transfected flu-
orescent lines. One to two cycles prior to assay set up,
parasites were removed from drug selection. Mid to late
trophozoite stage cultures (30-40 hours) were washed in
fresh culture medium (37°C), pelleted by centrifugation
then diluted to 0.5% to 1% parasitaemia at 1% haemat-
ocrit for a one cycle assay, or 0.1% to 0.3% parasitaemia at
1% haematocrit for a two cycle assay. Fresh culture
medium and fresh RBCs from two different donors
warmed to 37°C were used during assay set up.
Parasitized RBCs (25 μl to 50 μl) at the appropriate par-
asitaemia were added to a 96 well U-bottom plate (Fal-
con, Becton-Dickinson, Franklin Lakes, NJ, U.S.A.).
Inhibitory sample (2.5 μl to 5 μl for a 25 μl or 50 μl assay
respectively) was added to the parasitized RBCs giving a 1
in 10 dilution of sample in the assay (for a 1 in 20 dilution,
half the volume of sample would be added). All samples
were run in duplicate. A panel of non-immune sera from
Melbourne donors or PBS were included as non-inhibi-
tory controls. The 96 well plates were placed in a humidi-
fied air-tight gassed culture box at 37°C.
One cycle ring stage assays for microscopy and flow
cytometry were cultured for approximately 24 hours until
young rings were visible and no schizont stage parasites
remained. Thin smears of cell pellets were methanol fixed
and stained with 5% Giemsa (Merck, Darmstadt, Ger-
many). One thousand RBCs were counted for each slide.
Only early to late rings (0 to 20 hours old) were counted
as parasitized RBCs, with each infected RBC counted as a
single invasion event, regardless of how many parasites
were in the cell.
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invasion were cultured for 48 hours post set up until par-
asites were between 30-40 hours post invasion, when they
were prepared for flow cytometry analysis as appropriate.
Growth assays performed over two cycles of erythrocyte
invasion were supplemented with 5 μl to 10 μl (25 μl or 50
μl assay respectively) of fresh culture medium warmed to
37°C, 48 hours post set up (parasites 30-40 hours post
invasion). Ninety to 96 hours post assay set up the two
cycle trophozoite stage assays were prepared for flow
cytometry analysis. For non-fluorescent parasite lines,
RBCs were resuspended in 100 μl of PBS with 10 μg/ml
ethidium bromide (EtBr, Bio-Rad, Hercules, CA U.S.A.),
stained for one hour before centrifugation, removal of the
supernatant and resuspension in 200 μl of PBS. GFP fluo-
rescent parasite lines were resuspended in PBS to make a
final volume of 200 μl. Parasitaemia was measured on a
Becton Dickinson FACSCalibur (Franklin Lakes, NJ,
U.S.A.) flow cytometer using a 488 nm laser for excitation
of both GFP fluorescent (Fl-1) and EtBr stained (Fl-2)
parasites. Typically, 50,000 to 80,000 RBCs were counted
in each well. Samples were analysed using FlowJo soft-
ware (Tree Star Inc, Ashland, OR, U.S.A.) by first gating
for intact erythrocytes by side scatter and forward scatter
parameters, and subsequently determining the propor-
tion of FL1 or FL2 positive cells.
In this study, when results for both the parental
PcMEGF and PfM3'lines and the GFP fluorescent PcPHG
and PfPHG lines (described following) are described they
will be referred to as the PcMSP1-19 and PfMSP1-19
lines, respectively. For both the PcMSP1-19 and PfMSP1-
19 lines, parasite growth (G) was determined by dividing
the mean parasitaemia of duplicate wells for a test sample
(Smean) by the mean parasitaemia of two or more wells of
non-inhibitory control (Cmean) and multiplying by 100 (G
= {Smean/Cmean}*100).
Samples used in growth inhibition assays included rab-
bit polyclonal antibodies raised against recombinant P.
falciparum or P. chabaudi MSP1-19 [39], an inhibitory
MAb raised against 3D7 AMA1 (1F9) [49,50], the anti-
malarial drugs chloroquine (Sigma Aldrich, St Louis, MO
U.S.A.) and quinine (Sigma Aldrich, St Louis, MO
U.S.A.), serum samples from residents of Melbourne,
Australia, and archived serum samples from malaria-
exposed adult residents of Papua New Guinea. Ethical
consent for the use of human samples and blood products
was obtained from the Walter and Eliza Hall Institute,
and the Medical Research Advisory Council, PNG. All
human samples were collected following informed con-
sent. Serum samples were heat inactivated at 56°C for 45
minutes prior to use in assays.
Construction of GFP plasmids for transfection
GFP plasmids for the transfection of the PfM3' and
PcMEGF MSP1-19 transfected parent lines [39,51] were
modified from plasmids using Gateway ™ recombination
technology (Invitrogen, Carlsbad, CA, U.S.A.) as
described by Tonkin et al [52]. Briefly the pHGB pENTR
vector [52] was digested with the restriction enzyme Xho
I and gel extracted (Qiagen, Valencia, CA, U.S.A.) P. falci-
parum Rep20 sequence [53] was inserted 3' of the P. ber-
ghei DHFR terminator sequence. The resulting plasmid,
pHGBr, was digested with the restriction enzymes Bgl II
and Pst I and the original GFP sequence, which lacked a
start codon, was replaced with a GFP mutation II
sequence [54] containing a start codon to produce the
plasmid pHGBr(ATG). The 5'flanking region of the hsp86
promoter that controls GFP expression in this plasmid
has been described previously [55].
The pHrBl-1/2 destination vector described by Tonkin
et al [52] containing the blasticidin-S-deaminase gene
coding for resistance to blasticidin-S-HCl [56] was used
as the destination vector in LR clonase reactions with the
pHGBr(ATG) ENTR vector described above. The LR
Clonase reactions were performed according to manufac-
turers instructions (Invitrogen, Carlsbad, CA, U.S.A.).
The pHrBl-1/2 destination vector (2 μl) was mixed with 5
μl of the pHGBr(ATG) ENTR vector at equal concentra-
tions (approximately 300 ng). Four microlitres of 5 × LR
Clonase reaction buffer and 4 μl of LR Clonase enzyme
mix were added (Invitrogen, Carlsbad, CA, U.S.A.). The
reaction mixture was made up to 20 μl with TE Buffer
(pH 8.0) and the reaction allowed to proceed for 1 hour at
room temperature. The reaction was stopped by the addi-
tion of proteinase K (Roche Diagnostics, Mannheim,
Germany) and incubation at 37°C for 10 minutes. The LR
clonase reactions were then transformed directly into
CcdB sensitive electrocompetent bacterial cells. The
presence of the pHGBrHrBl-1/2 vector (Figure 1) in bac-
terial clones was confirmed by restriction digest. Plas-
mids for transfection were purified from 500 μl of
bacterial culture using a Plasmid Maxi kit (Qiagen, Valen-
cia, CA, U.S.A.) according to manufacturers instructions.
Transfection of parasites with fluorescence plasmids
Transfection of P. falciparum parasites PfM3' and
PcMEGF with the pHGBrHrBl-1/2 plasmid was under-
taken as described previously [57] using modified elec-
troporation conditions [58]. Briefly, approximately 70 μg
of purified plasmid DNA was resuspended in 15 μl of
warm TE buffer. Three hundred and eighty five
microlitres of sterile, warm (37°C) cytomix (120 mM KCl,
0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM
K2HPO4/KH2PO4 pH 7.6, 25 mM HEPES pH 7.6) were
added to the plasmid and then mixed with 200 μl of
infected RBC with 5-8% ring stage parasites before being
transferred to a 0.2 cm electroporation cuvette. The cyto-
mix and infected RBC mix was electroporated at 950 μF
capacitance and 0.31 kV (Biorad Gene Pulser II, Biorad,
Hercules, CA, U.S.A.) and the infected red blood cells
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containing 2% haematocrit RBCs, placed into a airtight
gassed chamber and incubated at 37°C.
Drug cycling commenced two days after transfection
using 5 μg/ml of blasticidin-S-HCl to select for fluores-
cent parasites with 24 ng/ml of pyrimethamine added to
maintain integration of the MSP1-19 transfection vec-
tors. After the second cycle of drug selection, fluorescent
parasites expressing GFP were cloned by limiting dilution
for use in experiments. In order to ensure maintainance
of both the MSP1-19 and GFP transfection plasmids for
experiments, cloned parasites were cultured with the
appropriate drugs (pyrimethamine and blasticidin-S-
HCl, respectively). Typically, there was no evidence for
the loss of GFP fluorescence or expression of the P. cha-
baudi MSP1-19 phenotype with up to two months of
continuos culture. To explore whether other isolates
could be successfully transfected with the same plasmid,
isolates CS2 and E8B, derived from the ITG line, were
also transfected.
Successful transfection of parasites with GFP plasmids
was confirmed by live parasite fluorescence microscopy
using an upright Zeiss Axioskop fluorescence microscope
(Carl Zeiss, Jena, Germany) with parasite nuclei stained
with 0.5 μg/ml DAPI (Sigma Aldrich, St Louis, MO,
U.S.A.). For flow cytometry GFP fluorescent lines were
stained with EtBr and the number of fluorescent parasites
were quantified using a FACSCalibur and analysed using
FlowJo software.
Results
Inhibitory polyclonal and monoclonal antibodies
Polyclonal rabbit antibodies raised against PfMSP1-19
and PcMSP1-19 and a MAb raised against 3D7 AMA1
[49,50] were tested against PfMSP1-19 and PcMSP1-19
lines for growth-inhibitory activity; the PcMSP1-19 line
contains the orthologous P. chabaudi MSP1-19 sequence
in place of the endogenous P. falciparum sequence [39].
The PfMSP1-19 rabbit antiserum was found to specifi-
cally inhibit growth of the PfMSP1-19 line. PcMSP1-19
specific rabbit antiserum and purified IgG specifically
inhibited growth of the PcMSP1-19 line. The AMA1
MAb which recognizes a region of P. falciparum AMA1
domain 1 common to both the 3D7 and D10 parasite
lines showed similar levels of growth inhibition of the
PfMSP1-19 and PcMSP1-19 lines at a concentration of
0.5 mg/ml. The reproducibility of PfMSP1-19 specific
rabbit antibodies in growth inhibition assays was con-
firmed in repeat experiments throughout the course of
this study in both one cycle and two cycle assays (Figure
2).
Optimisation of flow cytometry based growth assays
Prior studies using transgenic parasites to measure
MSP1-19 specific inhibitory antibodies have been largely
performed using microscopy-based assays, rather than by
flow-cytometry, and there are limited data on conditions
that influence growth-inhibition assay results or on assay
reproducibility. Therefore, studies were performed to
optimize flow cytometry-based growth inhibition assays.
Different assay start parasitaemias were examined in
order to determine the optimal conditions for measuring
parasite growth inhibition. PfMSP1-19 parasite growth
over one cycle in the presence of rabbit antisera or
malaria exposed human samples showed a strong correla-
tion between experiments using a starting parasitaemia
of 0.5% and 1% (r = 0.95, n = 13, p < 0.0001). Two cycle
assays set up at 0.05%, 0.1% and 0.3% parasitaemia
showed a strong correlation between PfMSP1-19 growth
for the 0.05% and 0.1% assays (r = 0.95, n = 13, p < 0.0001)
and the 0.1% and 0.3% assays (r = 0.98, n = 8, p < 0.0001).
These data suggest the start parasitaemia was unlikely to
influence the sensitivity of parasite growth inhibition
assays over the range of starting parasitaemia tested.
MSP1-19 specific rabbit antisera and the AMA1 MAb
were compared in one cycle and two cycle growth inhibi-
tion assays to determine whether a second cycle of para-
site growth would increase the sensitivity of the assay.
Growth of the PcMSP1-19 parasite line in the presence of
inhibitory antibodies showed that a second cycle
increased antibody mediated growth inhibition for both
the PcMSP1-19 and AMA1 antibodies but not the
PfMSP1-19 antibodies (Figure 3A). Similarly, growth of
the PfMSP1-19 line was considerably lower after two
Figure 1 Green fluorescent protein (GFP) transfection plasmid. 
Plasmid pHGBrHrBl-1/2 was constructed and used to transfect P. falci-
parum blood-stage parasites in vitro. Letters and numbers forming the 
name of the plasmid are in bold. The plasmid has the Hsp86 5' promot-
er driving GFP expression with a P. berghei 3' terminator region (B), and 
rep20 targeting sequence. The drug cassette contains the PfHrpIII 5' 
promoter driving blasticidin-S-deaminase (BSD) (Bl) with a PfHrpII 3' 
terminator. Fluorescence and drug cassettes are orientated in a head 
to tail orientation (5' to 3' end followed by 5' to 3' end) (1/2).
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cific antibodies but not the PcMSP1-19 antibodies (Fig-
ure 3B). These data suggest that a second cycle of parasite
growth increases growth inhibition due to antibodies
compared to one cycle assays. Inhibition by MSP1-19
specific antibodies over two cycles of parasite replication
was approximately double that observed in one cycle
assays.
A number of published studies comparing growth of
the PcMSP1-19 line and the PfMSP1-19 line have used a 1
in 20 volume of sample in one cycle microscopy based
assays [36-39]. For the purposes of this study, an assay set
up modified from Perrson et al [43] using a 1 in 10 sample
dilution was compared to a 1 in 20 sample dilution in one
cycle flow cytometry based assays with MSP1-19 specific
rabbit antisera. Growth of the PcMSP1-19 transfected
line when PcMSP1-19 antisera was added was higher for
the 1 in 20 dilution assay than the 1 in 10 dilution assay
(Figure 3C). Similarly PfMSP1-19 line growth in the pres-
ence of PfMSP1-19 antisera at a 1 in 20 dilution was
higher than at a 1 in 10 dilution (Figure 3D). The specific-
ity of the MSP1-19 rabbit antisera was confirmed by the
absence of a dose-response inhibitory effect on the con-
trol MSP1-19 line for PfMSP1-19 or PcMSP1-19 antibod-
ies (i.e. PfMSP1-19 antibodies did not substantially
inhibit the PcMSP1-19 line, or vice-versa). Similarly,
median growth of the PfMSP1-19 transfected parasite
line in a 1 in 10 dilution experiment for a panel of malaria
exposed non-dialysed adult samples (n = 15) was lower
(growth 59.2%) compared to the median growth for 1 in
20 dilution experiments (growth 85.6%) relative to con-
trol in one cycle experiments indicating an inhibitory
dose response effect of human samples on parasite
growth.
Transfection of MSP1-19 chimeric lines with green 
fluorescent protein (GFP)
The PfM3' and PcMEGF MSP1-19 lines developed by
O'Donnell et al [39,51] were transfected with a plasmid
expressing GFP under Blasticidin HCl drug selection
(transfection of PfM3' leading to PfPHG, transfection of
PcMEGF leading to PcPHG). Fluorescence microscopy
indicated that GFP fluorescence was not targeted to spe-
cific organelles but instead coloured the whole parasite
Figure 2 Specificity and reproducibility of growth inhibition by PfMSP1-19 specific antibodies. PfMSP1-19 specific inhibitory rabbit antiserum 
was added at a 1 in 10 dilution in two cycle growth assays. Growth is expressed as a percentage of controls (sera from non-exposed Australian resi-
dents). Results are from 8 different experiments carried out between December 2005 and July 2007. Assays were performed in duplicate and values 
represent the mean + range.
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detectable in all asexual stages of the life cycle.
The fluorescence profile of both EtBr stained and
unstained PfPHG GFP expressing parasites was exam-
ined during the course of the asexual parasite lifecycle.
GFP fluorescence profiles for early ring stage parasites (2,
6-10, 14-18 hours post invasion) separated clearly from
the uninfected RBC population (Figure 4B,D). This
allowed the parasitaemia of GFP fluorescent parasites to
be measured by flow cytometry at any stage of the para-
site life cycle, including early rings. As the parasites
matured, the mean fluorescence intensity (MFI) of GFP
positive parasites increased. There was a consistent
increase in MFI associated with time post invasion (Fig-
ure 4B). GFP fluorescence was not influenced by whether
or not the parasites had been stained with EtBr. EtBr
stained parasite fluorescence peaked around 36-40 hours
post invasion, with a noticeable increase in mean fluores-
cence intensity from approximately 22-26 hours to 36-40
hours post invasion (Figure 4C). Early ring stage parasites
(0-12 hours post invasion) stained with EtBr generally
separated poorly from the RBC population (Figure 4E).
Although the vector was designed to transfect the D10
PcMEGF and PfM3' lines, the same vector was success-
fully used to transfect other parasite lines, CS2 and E8B;
fluorescence was confirmed by flow cytometry and
immunofluorescence microscopy. Other vectors could be
generated for specific applications.
Validation of GFP fluorescent parasites in growth assays 
using inhibitory antibodies and anti-malarial drugs
There was a strong correlation between GFP fluorescence
and EtBr staining for measurements of PfPHG parasite
growth in two cycle assays (r = 0.97, n = 57, p < 0.0001) in
the presence of inhibitory and non-inhibitory samples.
Growth of the PfPHG GFP expressing line also correlated
strongly with growth of the PfM3' parent line in inhibi-
tory and non-inhibitory samples for two cycle assays (r =
0.88, n = 27, p < 0.0001).
Inhibition of parasite growth by antibodies for the
PcPHG and PfPHG fluorescent lines was compared to
inhibition of the PcMEGF and the PfM3' parent lines in
two cycle assays. Growth of the PcPHG GFP expressing
line was found to be the same as the PcMEGF non-GFP
Figure 3 Optimisation of growth inhibition assays. Comparison of one and two cycle parasite growth inhibition assays using the 3D7 AMA1 (1F9) 
monoclonal antibody (0.5 mg/ml), PfMSP1-19 rabbit antiserum (1 in 10 dilution) and PcMSP1-19 rabbit antiserum (1 in 10 dilution) for (A) the PcMSP1-
19 parasite line and (B) the PfMSP1-19 parasite line. Comparison of parasite growth inhibition by samples tested at either 1 in 10 or 1 in 20 dilution in 
a one cycle growth assay for (C) the PcMSP1-19 and (D) the PfMSP1-19 parasite lines. Growth is expressed as a percentage of controls (sera from non-
exposed Australian residents). The mean of duplicate or multiple values is shown and error bars represent the range when tested in duplicate or stan-
dard error of the mean for 4 or more values as appropriate.
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cific antiserum, P. falciparum MSP1-19 specific antise-
rum (Figure 5A) and AMA1 MAb. Similarly, growth of
the PfPHG GFP expressing line and the PfM3' non-GFP
parent line was found to be the same in the presence of P.
chabaudi MSP1-19 specific antiserum, P. falciparum
MSP1-19 specific antiserum (Figure 5B) and AMA1
MAb, as expected. The level of inhibition between the
parent and GFP transfected lines in the presence of
MSP1-19 specific rabbit antisera was reproducible over
multiple assays.
The utility of GFP-fluorescent lines in growth assays
was also evaluated with anti-malarial drugs. The growth
of PfPHG parasites in the presence of the anti-malarial
drugs chloroquine (Figure 5C) and quinine (Figure 5D)
showed a strong correlation between measurements
Figure 4 GFP fluorescent P. falciparum and changes in fluorescence over the course of the parasite asexual lifecycle. (A) Trophozoite stage 
PfM3' parasite transfected with the pHGBrHrBl-1/2 plasmid expressing GFP. Selected images show GFP fluorescence, DAPI staining of the nucleus, and 
bright field image showing the infected erythrocyte. Merged images demonstrate GFP fluorescence appears largely restricted to the parasite cytosol. 
(B) Changes in GFP mean fluorescence intensity of tightly synchronized PfPHG parasites followed through 48 hours of the parasite lifecycle by flow 
cytometry (detected in channel Fl-1). (C) Changes in EtBr mean fluorescent intensity (detected in channel FL-2) of the same parasites stained with 10 
μg/ml EtBr followed through 48 hours of the parasite lifecycle. Detection of early ring stage parasites by flow cytometry using (D) GFP fluorescence 
or (E) EtBr fluorescence highlighting the poor separation commonly seen between EtBr stained rings and uninfected RBCs.
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mature trophozoite stage detected by GFP fluorescence
or EtBr fluorescence. The correlation between parasitae-
mia measured by GFP and EtBr in the presence of chloro-
quine and quinine indicated that the two methods were
equally sensitive. There was no evidence that either
method was significantly overstating parasitaemia due to
increased background reading.
Taken together, these data suggest that expression of
GFP does not alter parasite susceptibility to inhibitory
antibodies or anti-malarial drugs. GFP fluorescent para-
sites are potentially a useful tool for measurement of par-
asite growth inhibition in in vitro assays.
Measurement of parasitaemia by microscopy versus flow 
cytometry
Further studies were performed to evaluate flow-cytome-
try-based measurements of parasitaemia compared to
microscopy. In total, 55 samples, including inhibitory
antibodies and serum samples from malaria-exposed and
non-exposed donors were compared between micros-
copy and flow cytometry based measurements of parasite
growth for duplicate wells across three experiments.
Counts for 15 samples by a second microscopist were
available for comparison. There was noticeable variation
in measurements by microscopy between duplicate wells
for both the PcMSP1-19 line (correlation between wells r
= 0.76, n = 70, p < 0.0001, mean difference in parasitae-
mia between duplicate wells 0.8%, range 0% to 5.5%) and
the PfMSP1-19 line (r = 0.80, n = 70, p < 0.0001, mean dif-
ference in parasitaemia between duplicate wells 0.7%,
range 0% to 2.8%, Figure 6A). In contrast, for flow cytom-
etry based assays, there was a very strong correlation
between measurements of parasitaemia for duplicate
wells for both the PcMSP1-19 (r = 0.99, n = 55, p < 0.0001,
mean difference in parasitaemia between duplicate wells
0.1%, range 0% to 0.3%) and PfMSP1-19 (r = 0.98, n = 55,
p < 0.0001, mean difference in parasitaemia between
duplicate wells 0.1%, range 0% to 0.7%, Figure 6B) lines.
The reproducibility of parasitaemia measurements was
examined for a single experiment where counts for dupli-
cate wells were available for two microscopists (M1 and
M2) and a flow cytometry based assay. Measurements of
parasitaemia between duplicate wells were compared for
all samples and control treatments (n = 13) in the experi-
ment for both the PcMEGF and PfM3' parasite lines. The
Figure 5 Measurement of growth inhibitory activity of antibodies and anti-malarial drugs using GFP fluorescent parasites. Comparison be-
tween the GFP transfected PcPHG and PfPHG lines and the parental parasites (PcMEGF and PfM3', respectively) of growth-inhibitory activity of (A) 
PcMSP1-19 specific rabbit antisera and (B) PfMSP1-19 specific rabbit antisera. Results represent data from three independent two cycle growth assays 
with samples tested at 1 in 10 dilution. Growth is expressed as a percentage of controls (sera from non-exposed Australian residents) and values rep-
resent means with SEM. Inhibition of the PfPHG parasite line by (C) chloroquine and (D) quinine in a one cycle growth assay. Parasitaemia was mea-
sured by flow cytometry using ring stage GFP fluorescence, late trophozoite stage GFP fluorescence or late trophozoite stage EtBr fluorescence. 
Growth is expressed as a percentage of PBS control.
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Page 9 of 12mean percentage difference in parasitaemia counts
between duplicates wells for all treatments and both lines
in the flow cytometry based assay was 0.2% (range 0% to
0.7%). The mean percentage difference between duplicate
wells across all serum treatments for M1 was 0.6% (range
0% to 1.6%). For M2 the mean percentage difference
between duplicate wells across all serum treatments was
1.5% (range 0% to 5.5%).
Comparison between microscopist M1, microscopist
M2 and flow cytometry based counts of parasitaemia
Figure 6 Measurement of parasite growth inhibition by microscopy and flow cytometry. Correlation between duplicate wells of parasitaemia 
counts from a growth inhibition assay using (A) ring stage microscopy (n = 70) or (B) flow cytometry (n = 55). The higher number of samples available 
for ring stage microscopy reflects the availability of counts from a second microscopist. The PfMSP1-19 line was used in this comparison and tested 
for inhibition by rabbit anti-MSP1-19 antibodies and a selection of samples from malaria-exposed and non-exposed donors. (C) Mean parasitaemia 
counts for duplicate wells determined by ring stage microscopy counts for microscopist one (M1) and microscopist two (M2) compared to parasitae-
mia measured by flow cytometry (trophozoite stage parasites) using the PcMSP1-19 and PfMSP1-19 lines. Samples used were serum from malaria ex-
posed individuals and unexposed controls numbered 1-26 for ease of comparison.
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Page 10 of 12(mean of duplicate wells) suggested that the counts for
M1 (mean of all samples 3.6%) tended to underestimate
parasitaemia relative to flow cytometry counts (mean
4.9%), while the counts of M2 (mean 5.7%) tended to
overestimate parasitaemia relative to flow cytometry
(Figure 6C). The comparison also highlights where para-
sitaemia counts from both microscopists differed widely
to that of the flow cytometry parasitaemia counts for
individual samples.
Discussion
In this study, flow cytometry-based growth inhibition
assays [43] were further evaluated and optimized and
GFP-fluorescent lines were developed and validated for
use in measuring growth-inhibitory antibodies and the
activity of anti-malarial agents. Inhibition of parasite
growth in the presence of MSP1-19 specific rabbit anti-
sera [39], AMA1 MAb [49,50] and human samples from
malaria-exposed individuals was higher in two cycle
assays than in one cycle assays, as previously reported
[43]. Similarly, MSP1-19 specific rabbit antisera and
human samples were more inhibitory at a 1 in 10 dilution
than a 1 in 20 dilution. Assay starting parasitaemia did
not appear to affect the level of parasite growth inhibition
for inhibitory samples. There was a strong correlation
between duplicate wells and repeat experiments for both
one cycle and two cycle flow cytometry based assays as
reported previously [43,48]. Importantly, the level of inhi-
bition for all three inhibitory antibodies was found to be
highly reproducible throughout the course of the study
for both one cycle and two cycle assays.
GFP fluorescent PcMSP1-19 and PfMSP1-19 parasites
were developed to reduce handling and improve sensitiv-
ity in flow cytometry based growth assays; parasites were
transfected to express GFP under control of the HSP-86
promoter on both the PcMEGF (PcPHG) and PfM3'
(PfPHG) parent line backgrounds and parasites were
cloned for subsequent use. Parasites expressing cytoplas-
mic GFP were easily detectable by flow cytometry and
measurements of parasitaemia correlated strongly
between GFP fluorescent parasites and parasites detected
using the established method of staining with ethidium
bromide.
There are several advantages of using GFP-fluorescence
compared to nucleic acid dyes to detect parasitaemia.
The use of the GFP fluorescent parasites removed the
need to use a nucleic acid stain for parasite detection by
flow cytometry, thereby reducing handling, and gave bet-
ter resolution between ring stage parasites and unin-
fected RBCs by flow cytometry compared to EtBr stained
rings. Furthermore, fluorescent parasites can be sorted
using flow cytometry and used in down-stream applica-
tions that require live viable parasites, which can be prob-
lematic with nucleic acid dyes [59,60]. Detection of GFP
fluorescent parasites was found to be as reliable as detec-
tion using EtBr stain in flow cytometry based growth
assays, with strong correlations between measured para-
sitaemia for both one cycle and two cycle growth assays.
Growth of GFP transfected and parental parasites was
found to be comparable in the presence of MSP1-19 spe-
cific inhibitory rabbit antisera, inhibitory AMA1 MAb
and malaria exposed human samples. This suggests that
parasites expressing GFP are a valid and reliable alterna-
tive to the use of a nucleic acid stain such as EtBr for
counting parasitaemia by flow cytometry in in vitro
assays. These studies demonstrate that GFP-fluorescent
parasites could be used in assays to measure acquired
immunity or vaccine-induced responses in the develop-
ment and testing of blood-stage vaccines, or for screening
and evaluation of compounds with anti-malarial activity.
Finally, the measurement of parasitaemia by flow
cytometry was found to be more accurate and reproduc-
ible than microscopy. Reproducibility of parasitaemia
counts between duplicate wells was much higher for flow
cytometry than microscopy. Differences in parasitaemia
counts between duplicate wells of the same sample were
as high as 98% by microscopy, whereas parasitaemia
counts by flow cytometry were very similar for duplicate
wells of the same sample, suggesting that much of the
variation between duplicate wells in microscopy is caused
by observer error. There was also substantial variability in
results between microscopists.
Conclusions
The development and optimisation of flow cytometry
based growth inhibition assays using parasite lines trans-
fected to express GFP resulted in a highly reproducible
assay that was sensitive and suitable for measuring the
inhibitory activity of antibodies and anti-malarial agents.
Results were highly reproducible between experiments,
between duplicate samples and superior to microscopy.
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